MUC1 and neoplasm: Silencing of MUC1 also enhanced the anti-tumor efficacy of paclitaxel against paclitaxel-resistant cell line A549/PR in NSCLC via Bax and Caspase-3 upregulation and Bcl-2 downregulation (75).